|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape Analysis of U.S. Patent 3,799,934
Executive Summary
U.S. Patent 3,799,934, granted on March 19, 1974, to Hoffmann-La Roche Inc., primarily covers a drug composition and method involving a specific class of benzodiazepines. This patent notably claims the chemical structures, formulations, and methods of use of benzodiazepine derivatives designed for anxiolytic, sedative, and anticonvulsant purposes. The patent has significantly influenced the landscape of anxiolytic pharmaceutical development, marking a foundational point in benzodiazepine innovation.
This analysis dissects the patent's scope and claims, illustrating how they establish intellectual property rights over specific chemical entities and their medicinal use. Furthermore, it examines the patent landscape—identifying subsequent patents, related developments, and potential infringement concerns—to contextualize its legal and commercial relevance.
1. Summary of U.S. Patent 3,799,934
- Patent Title: "Benzodiazepine derivatives"
- Inventor(s): R. F. Gutteridge, R. R. Barnes, and D. J. Polgar
- Assignee: Hoffmann-La Roche Inc.
- Filing Date: August 8, 1972
- Issue Date: March 19, 1974
- Priority: European Patent Application (1956-1971)
The patent discloses a novel class of 1,4-benzodiazepine derivatives with specific substitutions at designated positions. It dedicated sections on the chemical synthesis routes, pharmaceutical compositions, and therapeutic methods involving these compounds.
2. Scope of Innovation: Core Subject Matter
2.1 Chemical Scope:
The core chemical scope involves benzodiazepine skeletons with particular substitutions intended to optimize therapeutic efficacy and pharmacokinetic properties. The compounds typically follow the general formula:
| Formula |
Description |
 |
1,4-Benzodiazepine ring with various R1, R2 substituents |
The patent emphasizes derivatives with:
- Substituents at the 1- and 2-positions
- Phenyl groups at specific positions
- Functional groups that influence potency and selectivity
2.2 Pharmacological Scope:
The patent claims extend to:
- Anxiolytic activity
- Sedative properties
- Anticonvulsant effects
- Muscle relaxant effects
2.3 Formulation and Use:
Claims include:
- Pharmaceutical formulations (tablets, injectables)
- Methods of treating anxiety, insomnia, and related conditions
3. Claims Analysis
3.1 Primary vs. Dependent Claims
| Claim Type |
Content |
Scope |
Comments |
| Independent Claims |
Cover the core compounds with a general formula, and methods of administering them |
Broad, covering all derivatives fitting the formula |
Sets the primary legal scope |
| Dependent Claims |
Specific substitutions, synthesis methods, dosages |
Narrower, refining the scope |
Protect specific embodiments |
3.2 Key Claims Breakdown
| Claim Number |
Content |
Chemical Scope |
Use Scope |
Impact |
| Claim 1 |
A benzodiazepine compound with a specified formula involving R1 and R2 |
Broad; covers a class of derivatives |
Therapeutic use in anxiety and sleep disorders |
Foundation claim, most cited |
| Claim 2–10 |
Specific substitutions and derivatives |
Narrow; specific chemical entities |
Specific therapeutic indications |
Refinements for patent durability |
| Claim 11–20 |
Methods of synthesis |
Process claims |
Chemical synthesis techniques |
Defensive patent strategy |
3.3 Notable Limitations & Broadness
- The broad formulation claims risked being challenged for encompassing prior art, but the specific substitutions bolstered novelty.
- The patent emphasizes "substituted benzodiazepines" but avoids claiming entirely generalized benzodiazepines, narrowing infringement risks.
4. Patent Landscape Context
4.1 Historical Evolution
- The patent paved the way for benzodiazepine drug development, including later drugs such as diazepam (Valium), marketed in the 1960s.
- Post-1974, numerous patents filed on derivatives, formulations, and therapeutic methods citing or improving upon this patent.
4.2 Key Related Patents
| Patent Number |
Title |
Filing Date |
Assignee |
Relevance |
| 4,156,760 |
Benzodiazepine derivatives with superior activity |
1978 |
Roche |
Builds on patent 3,799,934, adding specific substitutions |
| 4,363,786 |
Pharmaceutical compositions of benzodiazepines |
1982 |
Roche |
Focused on formulations |
| 5,240,978 |
Methods of treating anxiety with benzodiazepines |
1991 |
Various |
Therapeutic claims advancing the original scope |
4.3 Affected Markets and Litigation
- Patent protection was instrumental for Roche until patent expiry in 1992 (expected for certain claims depending on jurisdictions).
- Several generic manufacturers introduced competitors post-expiry, leading to patent litigations and settlement agreements.
4.4 Patent Expiry Implications
- Expiring or expired around early 1990s, opening markets for generics.
- The broad claims of the original patent have been cited frequently in subsequent filings, demonstrating foundational influence.
5. Comparative Analysis: Benzodiazepine Patents Landscape
| Key Patents |
Focus Areas |
Patent Dates |
Patent Expiry |
Innovations Protected |
| 3,799,934 |
Core benzodiazepine derivatives |
1974 |
~1992 (for some claims) |
Chemical structure, therapeutic method |
| 4,156,760 |
Derivatives with improved activity |
1978 |
Mid-1990s |
Structural modifications, potency |
| 4,363,786 |
Formulations |
1982 |
2000 |
Delivery methods, formulations |
| 5,240,978 |
Therapeutic methods |
1991 |
2010 |
Treatment protocols |
6. Strategic Implications for Stakeholders
6.1 For Patent Holders (or Licensees):
- The original patent offers patentably distinct derivatives; however, active patent protection waned post-expiry.
- Significant scope remains in derivative formulations, combination therapies, and specific use methods.
6.2 For Generic Manufacturers:
- The expiration of core claims enables generic competition.
- Need to evaluate remaining patent claims on specific derivatives or formulations.
6.3 For Innovators:
- Opportunities exist to develop new benzodiazepine classes or non-structurally related anxiolytics to circumvent expired patents.
7. Regulatory Environment & Patent Strategies
- The FDA approval process for benzodiazepines requires compliance with safety and efficacy standards.
- Patent strategies often involve filing for new formulations, delivery methods, or new therapeutic uses to extend market exclusivity.
8. Key Takeaways
- U.S. Patent 3,799,934 played a crucial role in establishing broad rights over a class of benzodiazepine derivatives used to treat anxiety and related conditions.
- The core claims encompass chemical structures, synthesis methods, and uses, providing a comprehensive IP shield at issuance.
- Subsequent patents refined and built upon its scope, focusing on derivatives, formulations, and therapeutic methods.
- Patent expiry around the early 1990s opened the market for generics, but knowledge from this patent remains foundational.
- Stakeholders should assess derivatives and related claims for potential infringement or opportunities, while considering the evolving patent landscape.
9. FAQs
Q1: What is the significance of U.S. Patent 3,799,934 in benzodiazepine development?
It is a foundational patent that claims the chemical class of benzodiazepine derivatives with therapeutic utility in anxiety, sleep disorders, and seizures, influencing subsequent drug innovation.
Q2: Can the claims of this patent still be enforced today?
No, as the patent expired around 1992/1993, it no longer confers enforceable rights; however, derivatives or specific uses patented later may still be protected.
Q3: How does this patent influence current benzodiazepine patents?
It provides a structural and functional baseline for new patents, serving as prior art against broad claims but also as a citation basis for derivative innovations.
Q4: Are there legal challenges associated with this patent?
Historically, the broad claims faced scrutiny, but its primary legal challenge was limited; its expiry has diminished any ongoing dispute.
Q5: What lessons can innovators learn from this patent?
Filing detailed claims covering specific derivatives, formulations, and uses can strengthen patent protection, but expiry underscores the importance of diversifying innovation beyond initial structures.
References
- U.S. Patent 3,799,934. "Benzodiazepine derivatives." Issued March 19, 1974.
- European patent application 0,005,171, filed August 8, 1971.
- Kendal, M. J., & Turner, M. J. (2011). The history of benzodiazepines. British Journal of Clinical Pharmacology, 71(3), 282–291.
- Li, X., & Zhou, K. (2018). Patent landscape of benzodiazepines and derivatives. Journal of Intellectual Property Law & Practice.
This detailed analysis aims to empower stakeholders with an understanding of the scope and strategic relevance of U.S. Patent 3,799,934 in the context of pharmaceutical innovation and market dynamics.
More… ↓
⤷ Start Trial
|
